National Ataxia Foundation (NAF) Calls on the FDA to Accept the NDA Filing for Troriluzole

It has been thirty years since the first specific genetic mutation was discovered for Spinocerebellar Ataxia (SCA), yet people with the disease continue to wait for the first treatment to be available.

With your help their wait may be over.

Troriluzole, an experimental drug being developed by Biohaven, has completed Phase 3 clinical trials. Although the results fell short of the primary endpoint across all SCA types, the full range of data demonstrated clinically meaningful benefits for SCA Type 3.

Biohaven's NDA filing showed that troriluzole may significantly delay disease progression and reduce falls. Unfortunately, the FDA issued a Refuse to File letter. People with SCA need a treatment – anything that has the potential to even incrementally slow the relentless progression of this disease or lessen symptoms.

Less than 60 seconds of your time can make a difference in the lives of patients with SCA3.

Please share the email below with your SCA patients so they too can have a voice!

Dear Patient:

The Spinocerebellar Ataxia (SCA) community needs your help. The FDA recently refused to file a New Drug Application for troriluzole, an investigational treatment for patients living with SCA Type 3. In the clinical trials troriluzole showed meaningful clinical benefit in delaying disease progression and reducing falls in people with SCA Type 3. The National Ataxia Foundation is gathering comments from the Ataxia community to present to the FDA to encourage them to review the data.

Let's join together to raise our voices and make our community heard!